press release

Feb. 1, 2022, 7:00 a.m. EST

Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call and Webcast on February 8, 2022

WALTHAM, Mass., (BUSINESS WIRE) -- Deciphera Pharmaceuticals, Inc. /zigman2/quotes/203556943/composite DCPH +2.05% today announced that it will report its fourth quarter and full year 2021 financial results on Tuesday, February 8, 2022.

In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, February 8, 2022, to discuss the Company’s financial results and provide a corporate update.

The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 8293127. A webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations . The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK [®] is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220201005106/en/

SOURCE: Deciphera Pharmaceuticals, Inc.

Investor Relations:
Maghan Meyers
Argot Partners
Deciphera@argotpartners.com
212-600-1902 Media:
David Rosen
Argot Partners
David.Rosen@argotpartners.com
212-600-1902

COMTEX_401551949/2456/2022-02-01T07:00:23

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

Copyright Business Wire 2022

/zigman2/quotes/203556943/composite
US : U.S.: Nasdaq
$ 13.92
+0.28 +2.05%
Volume: 916,428
July 6, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$903.19 million
Rev. per Employee
$357,911
loading...

Comtex

Partner Center

Link to MarketWatch's Slice.